US-based Gilead Sciences Inc., (NASDAQ: GILD) has announced an exclusive option and license agreement with Tubulis GmbH, a German firm. This agreement grants Gilead access to Tubulis’ proprietary Tubutecan and Alco5 platforms for the joint development of an antibody-drug conjugate (ADC) targeting solid tumors.
Financial Terms and Milestones of the Agreement
According to the agreement, Tubulis will receive an upfront payment of USD 20 million. Should Gilead decide to exercise its option, an additional option exercise fee of USD 30 million will be paid. Furthermore, Tubulis is eligible for development and commercialization milestone payments that could reach up to USD 415 million, alongside mid-single to low double-digit tiered royalties on sales of any marketed products emerging from the collaboration.
Responsibilities and Future Developments
Tubulis will take the lead on early-stage research and development activities for the ADC program. If Gilead chooses to exclusively license the program, it will assume responsibility for all subsequent development and commercialization activities related to the products resulting from this partnership.-Fineline Info & Tech
